Rein Therapeutics
RNTX
47 hedge funds and large institutions have $41.5M invested in Rein Therapeutics in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 10 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.02% less ownership
Funds ownership: 1.86% → 1.84% (-0.02%)
10% less funds holding
Funds holding: 52 → 47 (-5)
13% less capital invested
Capital invested by funds: $48M → $41.5M (-$6.46M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$427K |
| 2 |
BlackRock
New York
|
+$248K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$243K |
| 4 |
State Street
Boston,
Massachusetts
|
+$88.8K |
| 5 |
Millennium Management
New York
|
+$77.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$700K |
| 2 |
Renaissance Technologies
New York
|
-$274K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$269K |
| 4 |
VF
Virtu Financial
New York
|
-$209K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$192K |
RNTX Hedge Fund Activity: Q2 2021 in Review
47 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2021, worth a combined $41.5M — down 13% from $48M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RNTX and 6 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 14 added.
The largest buyer was William Blair & Company, adding an estimated $427K. The largest seller was Maven Securities, exiting entirely with an estimated $700K sold.
- 47 institutional investors held Rein Therapeutics (RNTX) as of Q2 2021, down from 52 in Q1 2021.
- Funds reported $41.5M of Rein Therapeutics stock for Q2 2021, down 13% quarter-over-quarter.
- 6 funds opened new Rein Therapeutics positions in Q2 2021 and 10 closed out, a net change of -4 holders.
- The largest Rein Therapeutics buyer in Q2 2021 was William Blair & Company, an estimated $427K added.
- The largest Rein Therapeutics seller in Q2 2021 was Maven Securities, an estimated $700K sold.
Based on aggregated 13F filings for Q2 2021.